<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10864199</article-id><article-id pub-id-type="pmc">2363246</article-id><article-id pub-id-type="pii">6691165</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1165</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Eatock</surname><given-names>M M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Anthony</surname><given-names>D A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>El-Abassi</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wilson</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Paul</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Soukop</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Evans</surname><given-names>T R J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>CRC Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow, G11 6NT, UK</aff><aff id="aff2"><label>2</label>Department of Radiology, Glasgow Royal Infirmary, Castle Street, Glasgow, G4 0SF, UK</aff><aff id="aff3"><label>3</label>Zeneca Pharmaceuticals, Alderley Park, Macclesfield, SK10 4TG, UK</aff><aff id="aff4"><label>4</label>Department of Medical Oncology, Glasgow Royal Infirmary, Castle Street, Glasgow, G4 0SF, UK</aff><pub-date pub-type="epub"><day>18</day><month>05</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>06</month><year>2000</year></pub-date><volume>82</volume><issue>12</issue><fpage>1925</fpage><lpage>1931</lpage><history><date date-type="received"><day>24</day><month>05</month><year>1999</year></date><date date-type="rev-recd"><day>11</day><month>02</month><year>2000</year></date><date date-type="accepted"><day>17</day><month>02</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>The standard treatment for advanced gastro-oesophageal cancer in the UK is epirubicin, cisplatin and continuous infusion 5-fluoruracil by an indwelling central venous catheter (ECF), which has significant morbidity. Raltitrexed (tomudex), a specific inhibitor of thymidylate synthase with a long plasma terminal half-life (50&#x02013;100 h) has activity in gastro-intestinal tract malignancy. To reduce the Hickman line-associated morbidity of ECF; we have conducted a dose-finding study of tomudex combined with epirubicin and cisplatin. Twenty-four patients (22 males, two female), median age 63 years (range 21&#x02013;75), ECOG performance status &#x02264; 2 with histologically proven, unresectable or metastatic gastric (14 patients), gastro-oesophageal junction (nine patients) or oesophageal (one patient) adenocarcinoma received treatment with 3-weekly cisplatin 60 mg m<sup>&#x02212;2</sup>, epirubicin 50 mg m<sup>&#x02212;2</sup>and tomudex at doses of 2 mg m<sup>&#x02212;2</sup>, 2.5 mg m<sup>&#x02212;2</sup>or 3 mg m<sup>&#x02212;2</sup>in successive cohorts. Six patients were treated per dose level with no intra-patient dose escalation. Dose escalation occurred after six patients had completed at least one cycle of chemotherapy at the previous dose level. After defining the maximum tolerated dose a further six patients were treated at the preceding dose level to assess toxicity at the proposed phase II dose. A total of 102 cycles (50&#x00025; completed 6 cycles) were administered. The dose-limiting toxicities are neutropenia and diarrhoea occurring in 2/6 patients at the 3 mg m<sup>&#x02212;2</sup>dose level. Of those patients evaluable for response, there were eight partial and one complete response (overall response rate 38&#x00025;). The median survival was 9.9 months. ECT is an active regimen in oesophagogastric adenocarcinoma. The recommended dose of tomudex for further study in combination with epirubicin and cisplatin is 2.5 mg m<sup>&#x02212;2</sup>. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>gastro-oesophageal cancer</kwd><kwd>epirubicin</kwd><kwd>cisplatin</kwd><kwd>tomudex</kwd><kwd>chemotherapy</kwd></kwd-group></article-meta></front></article>


